Basic information Safety Supplier Related
ChemicalBook >  Product Catalog >  API >  Nervous system drugs >  Antipsychotics >  Zuclopenthixol

Zuclopenthixol

Basic information Safety Supplier Related

Zuclopenthixol Basic information

Product Name:
Zuclopenthixol
Synonyms:
  • 4-[3-[(9Z)-2-Chloro-9H-thioxanthene-9-ylidene]propyl]-1-piperazineethanol
  • 4-[3-[(Z)-2-Chloro-9H-thioxanthen-9-ylidene]propyl]-1-piperazineethanol
  • cis-Clopenthixol
  • (Z)-4-(3-(2-Chlorothioxanthen-9-ylidene)propyl)-1-piperazineethanol
  • Clopentixol cis-(Z)-
  • Clopixol
  • Einecs 258-758-5
  • Unii-47isu063sg
CAS:
53772-83-1
MF:
C22H25ClN2OS
MW:
400.96
EINECS:
258-758-5
Product Categories:
  • Heterocycles
  • Intermediates & Fine Chemicals
  • Isotope Labelled Compounds
  • Pharmaceuticals
  • Sulfur & Selenium Compounds
Mol File:
53772-83-1.mol
More
Less

Zuclopenthixol Chemical Properties

Melting point:
56-60°C
Boiling point:
577.4±50.0 °C(Predicted)
Density 
1.289±0.06 g/cm3(Predicted)
storage temp. 
-20°C Freezer, Under Inert Atmosphere
solubility 
Chloroform (Slightly), Methanol (Slightly)
form 
Solid
pka
14.96±0.10(Predicted)
color 
White to Off-White
CAS DataBase Reference
53772-83-1
More
Less

Zuclopenthixol Usage And Synthesis

Description

Zuclopenthixol is a dopamine receptor antagonist (Kis = 9.8 and 1.5 nM for D1 and D2 receptors, respectively). It also binds to serotonin (5-HT) receptor subtypes 5-HT2 and 5-HT6, α1-adrenergic, and histamine receptors (Kis = 7.6, 3, 33, and 169 nM, respectively) but not α2-adrenergic receptors (Ki = >4,300 nM). Zuclopenthixol inhibits dopamine-induced accumulation of cAMP in rat striatal homogenates (IC50 = 330 nM; Ki = 16 nM). It decreases stereotypic behavior induced by methylphenidate in mice (ED50 = 0.8 μmol/kg) and by apomorphine in rats and dogs (ED50s = 6.0 and 1.3 μmol/kg, respectively). Zuclopenthixol (0.7 and 1.4 mg/kg, i.p.) administered prior to testing enhances memory retrieval in rats in an inhibitory avoidance task without affecting locomotor activity.

Description

Zuclopenthixol is a kind of antipsychotic agent. It is a thioxanthene-based neuroleptic with in vivo action similar to the phenothiazine antipsychotics through antagonizing D1 and D2 dopamine receptors. It has three major formulations form including zuclopenthixol decanoate, zuclopenthixol acetate, and zuclopenthixol dihydrochloride. It can be used for the treatment of schizophrenia and bipolar mania. Besides antagonizing the D1 and D2 dopamine receptors, Zuclopenthixol can also take effect through antagonizing alpha1-adrenergic and 5-HT2 receptors. It can also weakly block the histamine H1 receptor.

Chemical Properties

Pale Yellow Low Melting Solid

Uses

The cis(Z)-form of Clopenthixol. Thioxanthene neuroleptic. Antipsychotic.

Uses

The labelled cis(Z)-form of Clopenthixol. Thioxanthene neuroleptic. Antipsychotic.

Uses

Zuclopenthixol is an anti-psychotic drug. It is an inhibitor of coxsackievirus B3. Also, it is an intermediate used in the synthesis of Zuclopenthixol Decanoate (Z701490), which is used in the maintenance treatment of chronic schizophrenic patients. It is one of the three distinct formulations of Zuclopenthixol namely, zuclopenthixol dihydrochloride, zuclopenthixol acetate or Acuphase and zuclopenthixol decanoate.

Definition

ChEBI: The (Z)-isomer of clopenthixol.

Clinical Use

Antipsychotic for schizophrenia and other psychoses

Drug interactions

Potentially hazardous interactions with other drugs
Anaesthetics: enhanced hypotensive effects.
Analgesics: increased risk of convulsions with tramadol; enhanced hypotensive and sedative effects with opioids; increased risk of ventricular arrhythmias with methadone.
Anti-arrhythmics: increased risk of ventricular arrhythmias with anti-arrhythmics that prolong the QT interval - avoid with amiodarone and disopyramide.
Antibacterials: increased risk of ventricular arrhythmias with moxifloxacin and parenteral erythromycin - avoid
Antidepressants: increased level of tricyclics; possible increased risk of convulsions with vortioxetine.
Antiepileptics: anticonvulsant effect antagonised.
Antimalarials: avoid concomitant use with artemether/lumefantrine.
Antipsychotics: avoid concomitant use of clozapine with depot preparations in case of neutropenia; possible increased risk of ventricular arrhythmias with risperidone.
Antivirals: concentration possibly increased with ritonavir.
Atomoxetine: increased risk of ventricular arrhythmias.
Anxiolytics and hypnotics: increased sedative effects.
Beta-blockers: increased risk of ventricular arrhythmias with sotalol - avoid.
Cytotoxics: increased risk of ventricular arrhythmias with vandetanib - avoid; increased risk of ventricular arrhythmias with arsenic trioxide.

Metabolism

Metabolism of zuclopenthixol is by sulphoxidation, sidechain N-dealkylation and glucuronic acid conjugation.
The sulphoxide metabolites are mainly excreted in the urine while unchanged drug and the dealkylated form tend to be excreted in the faeces.

References

https://www.drugbank.ca/drugs/DB01624
https://en.wikipedia.org/wiki/Tiabendazole

ZuclopenthixolSupplier

Shanghai Boyle Chemical Co., Ltd.
Tel
Email
sales@boylechem.com
J & K SCIENTIFIC LTD.
Tel
010-82848833 400-666-7788
Email
jkinfo@jkchemical.com
Chembest Research Laboratories Limited
Tel
+86-21-20908456
Email
sales@BioChemBest.com
LGM Pharma
Tel
1-(800)-881-8210
Email
inquiries@lgmpharma.com
Chemsky(shanghai)International Co.,Ltd.
Tel
021-50135380
Email
shchemsky@sina.com